We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Solvent Exposure Poses Health Risk for Pathology Workers

By LabMedica International staff writers
Posted on 07 Jul 2011
Pathologists and laboratory technicians who handle organic solvents such as toluene and xylene are at increased risk of developing autoimmune connective tissue diseases.

A new study showed an occupational health hazard involving solvent use and Raynaud’s phenomenon (RP). More...
Other studies overseas have shown similar solvent associations, but not with people exposed to solvents at work.

“Our study of 341 medical laboratory workers indicates they are more likely to develop a condition called Raynaud’s phenomenon, if they are exposed to solvents such as toluene or xylene. This raises concerns they could then have further serious health complications later in life,” said lead investigator Gordon Purdie, at the department of medicine, University of Otago, (Wellington, New Zealand).

Raynaud’s phenomenon is characterized by vasoconstriction, or the narrowing of blood vessels in the hands and other extremities, and is characterized by pain, color changes, and tautness or fullness of the fingers or toes. For some people it is a symptom or precursor of scleroderma, a rare connective tissue disease affecting multiple systems in the body and mainly among women.

Lab workers who worked with acetone or chlorinated solvents, combined with xylene or toluene, doubled their risk of developing RP. Risk of developing severe RP was even greater, in fact nine times.

The mainly female laboratory workers (79%) who used solvents in this study had higher rates of RP. Those who had worked with xylene or toluene doubled their risk of developing severe RP.

The study was presented at the Australian Rheumatology Association Scientific Meeting in Brisbane (QLD, Australia), which was held from May 14-17, 2011. The study also appeared online in the June 2011 issue of the Journal of Rheumatology.

Related Links:

University of Otago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.